ACM
NAUT icon

Altium Capital Management’s Nautilus Biotechnolgy NAUT Stock Holding History

Altium Capital Management’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-286,383
Closed -$3.95M – 148
2021
Q1 		$3.95M Sell
286,383
-113,617
-28% -$1.57M 1.1% 32
2020
Q4 		$4.34M Buy
+400,000
New +$4.21M 1.62% 16

Other funds holding NAUT

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.01B AUM 2.93% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Altium Capital Management's NAUT Position: Q2 2021 in Review

Altium Capital Management sold out of Nautilus Biotechnolgy (NAUT) in Q2 2021, closing a stake of 286,383 shares — an estimated $3.95M sold.

Altium Capital Management first reported a position in NAUT in Q4 2020 and held it in 2 quarters. The position peaked at $4.34M in Q4 2020. 56 funds tracked by Wall St. Rank hold NAUT as of Q2 2021.

  • Altium Capital Management reported no remaining Nautilus Biotechnolgy position as of Q2 2021 after selling out during the quarter.
  • Altium Capital Management sold 286,383 Nautilus Biotechnolgy shares in Q2 2021, an estimated $3.95M.
  • Altium Capital Management first reported a position in Nautilus Biotechnolgy in Q4 2020 and held it in 2 quarters.
  • Altium Capital Management's Nautilus Biotechnolgy position peaked at $4.34M in Q4 2020.
  • 56 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2021.

Based on Altium Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.